Your session is about to expire
← Back to Search
This trial is testing pembrolizumab, a monoclonal antibody, in combination with radiation therapy or pembrolizumab alone compared to the usual approach of chemotherapy plus radiation therapy after surgery in treating patients with head and neck squamous cell carcinoma that has come back or patients with a second head and neck cancer that is not from metastasis.
- Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Oral Cancers
- Oropharyngeal Carcinoma
- Laryngeal Squamous Cell Carcinoma
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2021 Phase 3 trial • 453 Patients • NCT03066778
Awards & Highlights
Find a Location
Who is running the clinical trial?
- Group 1: Arm B (cisplatin, carboplatin, IMRT, PBRT)
- Group 2: Arm C (pembrolizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What illnesses does Pembrolizumab commonly target?
"Pembrolizumab is a useful medication for treating malignant neoplasms, unresectable melanoma, microsatellite instability high, and patients with a high risk of recurrence."
How many patients are enrolled in this clinical trial?
"The data on clinicaltrials.gov does show that this trial is currently looking for patients. The trial was first posted on 1/8/2021 and was last updated on 11/9/2022. They are hoping to enroll 282 participants from 94 different sites."
Do many hospitals in Canada offer this research opportunity to patients?
"There are 94 locations where this trial is currently accepting patients, which include MedStar Washington Hospital Center in Washington D.C., Cone Health Cancer Center in Greensboro, North Carolina, and Annie Penn Memorial Hospital in Reidsville, Pennsylvaniatar Washington Hospital Center in Washington D.C., Cone Health Cancer Center in Greensboro, North Carolina, and Annie Penn Memorial Hospital in Reidsville, Pennsylvania."
Does this research require participants to be of a certain age?
"This trial is seeking patients aged 18 to 79. However, there are currently 364 other trials underway for minors and 5417 for senior citizens."
Are new participants being accepted into this research project?
"That is correct. The clinical trial is actively recruiting patients, as indicated by the most recent update on 11/9/2022. This information can be found on clinicaltrials.gov, where the study was originally posted on 1/8/2021. Currently, 94 medical facilities are enrolling a total of 282 individuals in this research project."
What is the FDA's stance on Pembrolizumab?
"At Power, we gave Pembrolizumab a score of 2 on our safety scale. This is because while there is some data indicating that it is safe, there is no evidence yet to suggest that it actually works."
How can I become involved in this experiment?
"Carcinoma patients that are between 18 and 79 years old may be eligible for this study. If accepted, they would become one of the around 282 people in the trial."
What other investigations have included Pembrolizumab?
"Pembrolizumab was first pioneered at City of Hope Comprehensive Cancer Center in 1997 and, since then, 1918 trials have been completed. Right now, 2064 more are ongoing with a large portion taking place within Washingtone Cancer Center in 1997 and, since then, 1918 trials have been completed. Right now, 2064 more are ongoing with a large portion taking place within Washington D.C."
Share this study with friends